Changes to prothrombin international normalized ratio in patients receiving hemodialysis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 4, 2013, Pages 283-287

  Maruyama, Noriaki ^a   Abe, Masanori ^a   Okada, Kazuyoshi ^a   Soma, Masayoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anticoagulation; Hemodialysis; International normalized ratio; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; PROTHROMBIN; WARFARIN;

AGED; ALBUMIN BLOOD LEVEL; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; FEMALE; HEMODIALYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PROTHROMBIN TIME; THROMBUS; TREATMENT INDICATION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; RENAL DIALYSIS; SERUM ALBUMIN; WARFARIN;

EID: 84876568184     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201779     Document Type: Article

References (13)

1. Breckenridge A. Oral anticoagulant drugs: pharmacokinetic aspects. Semin Hematol. 1978; 15: 19-26.
2. Kelly JG, O'Malley K. Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinet. 1979; 4: 1-15. doi:10.2165/00003088-197904010-00001
3. Bennett WM, Aronoff GR, Morrison G, Golper TA, Pulliam J, Wolfson M, Singer I. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis. 1983; 3: 155-193.
4. Shetty HGM, Fennerty AG, Routledge PA. Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy. Clin Pharmacokinet. 1989; 16: 238-253. doi:10.2165/00003088-198916040-00003
5. Ganeval D, Fischer AM, Barre J, Pertuiset N, Dautzenberg MD, Jungers P, Houin G. Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. Clin Nephrol. 1986; 25: 75-80.
6. Matzke GR, Frye RF. Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. Drug Saf. 1997; 16: 205-231. doi:10.2165/00002018-199716030-00005
7. Marusic S, Gojo-Tomic N, Bacic-Vrca V, Franic M. Enhanced anticoagulant effect of warfarin in a patient treated with cloxacillin. Int J Clin Pharmacol Ther. 2012; 50: 431-433.
8. Yamamuro F, Miki A, Kondo G, Maeda T, Satoh H, Hori S, Sawada Y. Individual differences in prothrombin time-international normalized ratio variation following coadministration of the anticancer agents S-1 and warfarin: 3 case reports. Int J Clin Pharmacol Ther. 2011; 49: 700-704.
9. McCracken N, Lahu G, Bethke TD. Lack of pharmacokinetic and pharmacodynamic interactions of roflumilast with (R, S)-warfarin in healthy adult subjects. Int J Clin Pharmacol Ther. 2011; 49: 388-396.
10. Seliger SL, Gillen DL, Longstreth WT Jr, Kestenbaum B, Stehman-Breen CO. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int. 2003; 64: 603-609. doi:10.1046/j.1523-1755.2003.00101.x
11. Toyoda K, Fujii K, Fujimi S, Kumai Y, Tsuchimochi H, Ibayashi S, Iida M. Stroke in patients on maintenance hemodialysis: a 22-year single-center study. Am J Kidney Dis. 2005; 45: 1058-1066. doi:10.1053/j.ajkd.2005.02.028
12. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009; 20: 2223-2233. doi:10.1681/ASN.2008080824
13. Sood MM, Komenda P, Sood AR, Rigatto C, Bueti J. The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis? Chest. 2009; 136: 1128-1133. doi:10.1378/chest.09-0730